I found this on diaTribe, thought it might be helpful. It seems like there is emerging clinical data on benefits of GLP-1 to type 1s (Highlights from EASD 2021 | diaTribe) (the chart didn’t format when I pasted, but is in the link)
People with Type 1 Diabetes Could Benefit From SGLT-2s and GLP-1s
Though the Food and Drug Administration (FDA) has not approved the use of either SGLT-2 inhibitors or GLP-1 receptor agonists for people with type 1 diabetes, researchers are gathering data to determine whether the benefits could outweigh potential risks.
The following three cohorts, summarized below, presented at the EASD 2021 conference included people with type 1 diabetes who used either an SGLT-2 inhibitor or GLP-1 receptor agonist. Results from the studies on these cohorts showed that liraglutide (a GLP-1 medication) was found to improve (depending on the size of the dose) glucose management, reduce body weight, and lead to reduced insulin needs when compared with a placebo.
Dapagliflozin (an SGLT-2) led to increases in TIR without any significant increase in hypoglycemia occurrences. And finally research out of Belgium showed that the use of SGLT-2s led to lower A1C, reduced weight, and reduced total insulin dose, but still resulted in a small number of diabetic ketoacidosis cases.
“I think certainly the use of SGLT2 inhibitors in people with type 1 diabetes should be considered as our data shows the importance of good patient selection,” said Falco van Nes, from UZ Gasthuisberg, in Leuven, Belgium. “Those who use insulin pumps or are at a low BMI you really have to be careful with it. It certainly has its place in type 1 diabetes but you really have to educate your patients very well and watch out for the side effects.”